Skip to main content

Table 2 Characteristics of active SLE patients with renal and non-renal involvement

From: High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus

  Renal active ( n = 19) Non-renal active ( n = 18)
No. male/female 5/14 2/16
Age (yrs), median (range) 38 (18 to 73) 37 (19.60)
SLEDAI, median (range) 12 (6 to 16) *** 8 (5 to 10)
Anti-dsDNA (E/ml), median (range) 230 (7 to 6,683) 234 (3 to 1,000)
C3 (g/l), median (range) 0.58 (0.21 to 1.12) * 0.91 (0.37 to 1.68)
C4 (g/l), median (range) 0.10 (0.04 to 0.30) 0.13 (0.02 to 0.27)
CRP (g/l), median (range) 5 (1 to 81) 9.5 (3 to 92)
No. with/without treatment 17/2 12/6
Users of Prednisone (%) Dose (mg/day), median (range) 14 (78%) 6.25 (2.5 to 100) 7 (39%) 7.50 (5 to 20)
Users of Azathioprine (%) Dose (mg/day), median (range) 2 (11%) 87.5 (75 to 100) 3 (17%) 125 (100 to 150)
Users of Hydroxychloroquine (%) Dose (mg/day), median (range) 8 (42%) 400 (200 to 400) 8 (44%) 400 (200 to 1,200)
  1. * Difference between renal active patients and non-renal active SLE patients. (*P < 0.05, *** P < 0.0001).
\